184 related articles for article (PubMed ID: 10905493)
1. Mechanism of troglitazone action in type 2 diabetes.
Petersen KF; Krssak M; Inzucchi S; Cline GW; Dufour S; Shulman GI
Diabetes; 2000 May; 49(5):827-31. PubMed ID: 10905493
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
4. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
6. Assessment of human muscle glycogen synthesis and total glucose content by in vivo 13C MRS.
Van Den Bergh AJ; Tack CJ; Van Den Boogert HJ; Vervoort G; Smits P; Heerschap A
Eur J Clin Invest; 2000 Feb; 30(2):122-8. PubMed ID: 10651836
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Park KS; Ciaraldi TP; Abrams-Carter L; Mudaliar S; Nikoulina SE; Henry RR
J Clin Endocrinol Metab; 1998 May; 83(5):1636-43. PubMed ID: 9589670
[TBL] [Abstract][Full Text] [Related]
9. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.
Mathieu-Costello O; Kong A; Ciaraldi TP; Cui L; Ju Y; Chu N; Kim D; Mudaliar S; Henry RR
Metabolism; 2003 May; 52(5):540-6. PubMed ID: 12759881
[TBL] [Abstract][Full Text] [Related]
10. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
[TBL] [Abstract][Full Text] [Related]
11. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes.
Cline GW; Petersen KF; Krssak M; Shen J; Hundal RS; Trajanoski Z; Inzucchi S; Dresner A; Rothman DL; Shulman GI
N Engl J Med; 1999 Jul; 341(4):240-6. PubMed ID: 10413736
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Miles PD; Romeo OM; Higo K; Cohen A; Rafaat K; Olefsky JM
Diabetes; 1997 Nov; 46(11):1678-83. PubMed ID: 9356012
[TBL] [Abstract][Full Text] [Related]
13. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
[TBL] [Abstract][Full Text] [Related]
14. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb.
Okuno A; Ikeda K; Shiota M; Fujiwara T; Yoshioka S; Sugano T; Horikoshi H
Metabolism; 1997 Jun; 46(6):716-21. PubMed ID: 9186311
[TBL] [Abstract][Full Text] [Related]
15. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
16. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats.
Oshida Y; Kako M; Nakai N; Shimomura Y; Li L; Sato J; Ohsawa I; Sato Y
Endocr J; 1999 Oct; 46(5):723-30. PubMed ID: 10670760
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
20. Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Levin K; Hother-Nielsen O; Henriksen JE; Beck-Nielsen H
Diabetes Care; 2004 Jan; 27(1):148-54. PubMed ID: 14693981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
